BASKING RIDGE, N.J., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS), a cell therapy company combining an industry-leading external development and manufacturing provider with a development pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and ischemic repair, announces today that the Company’s management will present at multiple conferences in October.
Stem Cell Meeting on the Mesa
- Website: www.stemcellmeetingonthemesa.com
- Venue: Estancia La Jolla Hotel, La Jolla, California
Session 1
- Date and Time: Wednesday, October 7, 2015, 7:15 AM PT
- Session Chair: Dr. Robert Preti, Senior Vice President, Development and Technical Operations and Chief Technology Officer, Caladrius; President of PCT
- Topic: Manufacturing & Scale-Up Workshop: Application of Traditional Drug & Biologics Development Principles to Regenerative Medicine
Session 2
- Date and Time: Wednesday, October 7, 2015, 11:00 AM PT
- Presenter: Dr.David Mazzo, Chief Executive Officer
- Topic: Company Presentation
Session 3
- Date and Time: Friday, October 9, 2015 10:15 AM PT
- Poster Presenter: Dr.Candice Junge, Associate Vice President, Clinical Strategy and Commercial Assessment
- Topic: Evaluation of Safety & Efficacy of Autologous Ex Vivo Expanded TRegs (CLBS03) for the Treatment of New Onset Type 1 Diabetes Mellitus in an Adolescent Population
Session 4
- Date and Time: Friday, October 9, 2015 10:15 AM PT
- Presenter: Dr.Gabriel Nistor, Vice President, Research
- Topic: Functional Properties of Patient-derived Melanoma Cancer Stem Cells Utilized as Treatment for Metastatic Melanoma in a Phase III Clinical Trial
Transcatheter Cardiovascular Therapeutics (TCT) 2015
- Website: http://www.crf.org/tct
- Venue: The Moscone Center, San Francisco, California
Session 1
- Date and Time: Thursday, October 15, 2015, 2:23 PM PT
- Lecturer: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: Cell-Based Therapies Prevent and Cure Heart Failure: More Than an Adventure
Session 2
- Date and Time: Thursday, October 15, 2015, 2:50 PM PT
- Discussant: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: Stem Cell Advances: Targeting Heart Failure
Session 3
- Date and Time: Thursday, October 15, 2015, 5:02 PM PT
- Discussant: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: Stem Cell Therapy Clinical Trials: Yes, We Can!
Cardiac Safety Research Consortium Sponsored Workshop for Cardiovascular Safety for Cell Therapies in Development for Cardiovascular Indications
- Date and Time: Friday, October 23, 2015, 10:35 AM ET
- Website: http://clbs.bio/csrcOct2015
- Venue: Sheraton College Park North Hotel, Beltsville, Maryland
- Presenter: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: Is Demonstration of Dose Dependency Required for Establishing Safety and Bioactivity
Cavendish Global Health Impact Forum
- Dates: Sunday, October 25 – Wednesday, October 28, 2015
- Website: http://cavendishglobal.com/2015-cleveland-clinic/
- Venue: Cleveland Clinic, Cleveland, Ohio
- Presenter: Dr.David Mazzo, Chief Executive Officer
- Topic: Company Presentation
2015 Till and McCulloch Meetings
- Date and Time: Tuesday, October 27, 2015, 11:25 AM ET
- Website: http://clbs.bio/tillmc15
- Venue: Sheraton Centre Hotel Toronto, Toronto, Ontario
- Presenter: Dr. Hans Keirstead, Senior Vice President, Research and Chief Science Officer
- Topic: Tumor-Initiating Cell-Based Immunotherapy for Cancer
Sofinnova Japan Biopharma Partnering Conference
- Date and Time: Tuesday, October 27, 2015, 9:05 AM JST
- Website: http://www.sofinnovajapanpartnering.com/
- Venue: Conrad Hotel, Tokyo, Japan
- Presenter: Dr. Douglas Losordo, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
- Topic: Company Presentation
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. For more information, visit www.caladrius.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company’s wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
CONTACT: Investor Relations: LHA Investor Relations Anne Marie Fields Senior Vice President Phone: +1-212-838-8377 Email: afields@lhai.com Media Relations: Caladrius Biosciences, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@caladrius.com
Help employers find you! Check out all the jobs and post your resume.
